ネパールの入院心臓病患者における潜在的薬物相互作用:前向きな観察研究
Binod Kumar Sah1,2, Arun Kumar Karna3, Sangam Subedi4
1Pharmaceutical Sciences Program, School of Health and Allied Sciences, Pokhara University, Pokhara, Gandaki, Nepal binodksah2073@gmail.com sunilcresta@gmail.com.
BMJ open
|August 22, 2025
まとめ
心血管疾患 (CVD) の患者では,潜在的薬物相互作用 (pDDI) の高頻度が見られた. 患者のケアを改善するために,定期的な薬のレビューと薬物相互作用のチェックが推奨されます.
科学分野:
- 薬理学について
- 臨床薬局
- 心臓病科
背景:
- 薬物相互作用 (DDI) は,特に心血管疾患 (CVD) の患者にとって,複雑な薬剤療法において,重大なリスクをもたらします.
- 心血管薬はしばしばDDIに関与し,慎重にモニタリングする必要があります.
研究 の 目的:
- 入院中のCVD患者における潜在的なDDI (pDDI) の頻度,重症度,およびリスク要因を決定する.
- 総合的なpDDI評価のために標準化されたインタラクションデータベースを使用する.
主な方法:
- 高等医療病院のCVD入院患者106人を対象とした前向きな横断的な研究です.
- Lexicomp DDIチェッカーを用いたpDDIの評価,重症度およびリスクによる分類
- PDDIに関連する要因を特定するためのバイナリロジスティック回帰分析
主要な成果:
- 患者の64. 2%が少なくとも1回のpDDIを経験した.
- ほとんどのpDDIは中程度の重症 (77. 3%) で,リスク評価はC (65. 7%) でした.
- 利尿剤,抗血小板剤,抗凝固剤,およびカルシウムチャネルブロック剤は,最も頻繁に関与する薬剤でした. 長期の入院,多剤療法,ICU入院は,pDDIの重要なリスク要因でした.
結論:
- この研究は,心血管疾患の入院患者の間でpDDIの高い罹患率を明らかにした.
- PDDIのリスクを軽減するために,定期的な薬剤のレビューと薬物相互作用のチェックを日常の心臓ケアに組み込むことをお勧めします.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:26Cardiac Catheterization IV: Nursing Management
193
Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...
193
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847